Open access
Oct 2026
177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial.
The phase 2 randomized LUNAR trial previously demonstrated that neoadjuvant 177Lu-PNT2002 before stereotactic body radiotherapy (SBRT) significantly improved progression-free survival (PFS) in patients with oligorecurrent hormone-sensitive prostate cancer (orHSPC). We report updated efficacy and safety outcomes with ex...
A. Kishan, H. Wilhalme, C. Felix et al.
· European Urology · 0 citations